Professor McCormack graduated in 2000 from the University of Sydney and undertook postgraduate training at the Royal North Shore Hospital. Her subsequent PhD examined the role of chemotherapy and genetic biomarkers in the management of aggressive pituitary tumours. In 2010 she completed a clinical and research fellowship in the Oxford Centre for Diabetes, Endocrinology and Metabolism, with a focus on pituitary tumours. She was then appointed to her current position as senior staff specialist in the Department of Endocrinology at St Vincent’s Hospital in 2011. She also heads The Hormones and Cancer Group at the Garvan Institute of Medical Research. Her primary research interests are in exploring the biology of aggressive pituitary tumours and investigating new treatment options. She also has research interests in pituitary tumour genetics. As a member for the European Society of Endocrinology’s Taskforce on Aggressive Pituitary Tumours, she was integral to the development of guidelines on the management of aggressive pituitary tumours published in 2017 and updated in 2024. She heads the St Vincent’s Campus pituitary multidisciplinary team, is chair of the Sydney Pituitary Collaborative Group (SPCG) and co-chair of the Australia New Zealand Pituitary Alliance (ANZPA). She is immediate past president of ESA.

Chris Yates completed his specialist training in Diabetes and Endocrinology at the Royal Melbourne Hospital and Western Health. Using continuous glucose monitoring, his PhD at the University of Melbourne investigated steroid induced diabetes in recent kidney transplant recipients. Alongside his PhD studies, Chris helped to establish the Royal Melbourne Fracture Liaison Service to improve the detection and treatment of osteoporosis. He then undertook a postdoctoral fellowship with Professor Rajesh Thakker at the University of Oxford studying the molecular biology of neuroendocrine tumours. He is now employed as an Endocrinologist at the Royal Melbourne Hospital, where he is the Stream Leader for Pituitary Tumours and Head of Bone and Mineral Medicine. He is also Co-Director of Endocrine Research at Western Health and Co-Chair of the Australian and New Zealand Pituitary Alliance. His current research interests include: the molecular pathogenesis of pituitary adenomas, the clinical utility of peripheral quantitative CT in fracture prediction, and the use of continuous glucose monitoring to assess steroid-induced diabetes.